Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia
A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
Radiation Alone Improves Outcomes in Early-Stage NLPHL Without High-Risk Features
Radiotherapy alone was associated with excellent progression-free survival (PFS) and low rates of late toxicity in patients with stages IA to IIA nodular lymphocyte-predominant...
Prophylaxis Does Not Fully Prevent VTE Risk in Patients With ALL Treated With Asparaginase
Antithrombin (AT) replacement and heparin prophylaxis was not entirely effective for the prevention of venous thromboembolism (VTE) in adult patients with acute lymphocytic leukemia...
International Prognostic Score Predicts Time to First Treatment in Patients With Early-Stage CLL
An international prognostic score (IPS-E) consisting of a sum score for three markers for consistently predicted time to first treatment (TTFT) in patients with...
Comparing Anticoagulant Effect of Edoxaban in Patients With Cirrhosis Against Healthy Controls
Edoxaban, an anti-factor Xa targeting direct oral anticoagulant (DOAC), is a less effective inhibitor of coagulation in patients with cirrhosis than in healthy individuals,...
IWG-PM Publishes Proposed Diagnostic Criteria for SF3B1-Mutant MDS
The International Working Group for the Prognosis of MDS (IWG-PM) has published a proposal for new diagnostic criteria for SF3B1-mutant myelodysplastic syndromes (MDS) as...
Predicting Survival in MM With Renal Impairment and Light Chain Cast Nephropathy
The quality of renal response to therapy was associated with survival in patients with multiple myeloma (MM) with renal impairment and light chain cast...
BTKi Improves Disease Control in CLL After Progression on Venetoclax
Treatment with a Bruton tyrosine kinase inhibitor (BTKi) showed efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed on venetoclax, according to...
Is NCCN-IPI a Better Prognostic Tool for DLBCL Treated With R-CHOP?
Compared with the widely used International Prognostic Index (IPI) and revised IPI (R-IPI), the most recent National Comprehensive Cancer Network IPI (NCCN-IPI) better predicts...
Ruxolitinib Improves Outcomes in Patients With Steroid-Refractory Graft-Versus-Host Disease
Patients with steroid-refractory acute graft-versus-host disease (GVHD) following hematopoietic cell transplant (HCT) experienced durable clinical responses by 28 days and had promising overall survival...
Current Issue
July 2020 Volume 6 Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
